Butterfly Medical Announces First BPH Clinical Study Procedures Performed in North America

Butterfly Medical, an Israeli medical device company developing a novel minimally invasive solution to treat Benign Prostatic Hyperplasia (BPH), today announced its first procedures performed in-office under local anesthesia in its clinical study in North America.

The clinical study evaluates the safety and effectiveness of Butterfly’s next generation prostatic retraction device: a proprietary nitinol implant designed to gently open and prevent the blockage from an enlarged prostate for improved urine flow and thereby alleviate the symptoms caused by BPH. It is considered a “next gen” BPH therapy as it is reversible while also not requiring heating, cooling, cutting or piercing of the prostate.

The first North American procedures were successfully performed by Dr. Steven Gange, (Salt Lake City, UT) clinical study Principal Investigator.

“Many men suffer severe urinary symptoms due to BPH, while also tolerating side effects of marginally effective medications. Today’s primary treatment is surgery, which many patients do not want,” said Dr. Steven Gange, board-certified urologist by the American Board of Urology. “This creates an excellent niche opportunity for minimally invasive BPH procedures like the Butterfly implant.”

The Butterfly procedure can be conducted under local anesthesia in an office setting usually in less than 10 minutes. It allows for faster recovery and reduced side effects such as retrograde ejaculation, pelvic pain and, removes the need for a catheter compared to previous BPH treatments.

Full article: